Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Bart Barlogie

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Multiple Myeloma

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Neoplastic Gene Expression Regulation

Anatomy

Plasma Cells

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Coleman Elizabeth Ann; Lynch Henry; Enderlin Carol; Stewart Beth; Thomé Stephan D; Kennedy Robert; Richardson-Nelson Tami; Barlogie Bart
Initial report of a family registry of multiple myeloma.
Sawyer Jeffrey R; Tian Erming; Thomas Edward; Koller Mark; Stangeby Colin; Sammartino Gael; Goosen Linda; Swanson Charles; Binz Regina L; Barlogie Bart; Shaughnessy John
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon.
Seckinger A; Meissner T; Moreaux J; Goldschmidt H; Fuhler G M; Benner A; Hundemer M; Rème T; Shaughnessy J D; Barlogie B; Bertsch U; Hillengass J; Ho A D; Pantesco V; Jauch A; De Vos J; Rossi J F; Möhler T; Klein B; Hose D
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Bart Barlogie (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Coleman Elizabeth Ann; Lynch Henry; Enderlin Carol; Stewart Beth; Thomé Stephan D; Kennedy Robert; Richardson-Nelson Tami; Barlogie Bart
Initial report of a family registry of multiple myeloma.
Cancer nursing 2009;32(6):456-64.
2009: Sawyer Jeffrey R; Tian Erming; Thomas Edward; Koller Mark; Stangeby Colin; Sammartino Gael; Goosen Linda; Swanson Charles; Binz Regina L; Barlogie Bart; Shaughnessy John
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon.
British journal of haematology 2009;147(4):484-94.
2009: Seckinger A; Meissner T; Moreaux J; Goldschmidt H; Fuhler G M; Benner A; Hundemer M; Rème T; Shaughnessy J D; Barlogie B; Bertsch U; Hillengass J; Ho A D; Pantesco V; Jauch A; De Vos J; Rossi J F; Möhler T; Klein B; Hose D
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
Oncogene 2009;28(44):3866-79.
2009: Shaughnessy John D; Zhou Yiming; Haessler Jeff; van Rhee Frits; Anaissie Elias; Nair Bijay; Waheed Sarah; Alsayed Yazan; Epstein Joshua; Crowley John; Barlogie Bart
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
British journal of haematology 2009;147(3):347-51.
2009: Zhou Y; Barlogie B; Shaughnessy J D
The molecular characterization and clinical management of multiple myeloma in the post-genome era.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(11):1941-56.
2009: van Rhee Frits; Szmania Susann M; Dillon Myles; van Abbema Anne M; Li Xin; Stone Mary K; Garg Tarun K; Shi JuMei; Moreno-Bost Amberly M; Yun Rui; Balasa Balaji; Ganguly Bishwa; Chao Debra; Rice Audie G; Zhan Fenghuang; Shaughnessy John D; Barlogie Bart; Yaccoby Shmuel; Afar Daniel E H
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Molecular cancer therapeutics 2009;8(9):2616-24.
2009: Anguiano Ariel; Tuchman Sascha A; Acharya Chaitanya; Salter Kelly; Gasparetto Cristina; Zhan Fenghuang; Dhodapkar Madhav; Nevins Joseph; Barlogie Bart; Shaughnessy John D; Potti Anil
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(25):4197-203.
2009: Bartel Twyla B; Haessler Jeff; Brown Tracy L Y; Shaughnessy John D; van Rhee Frits; Anaissie Elias; Alpe Terri; Angtuaco Edgardo; Walker Ronald; Epstein Joshua; Crowley John; Barlogie Bart
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
Blood 2009;114(10):2068-76.
2009: Pennisi Angela; Ling Wen; Li Xin; Khan Sharmin; Shaughnessy John D; Barlogie Bart; Yaccoby Shmuel
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.
Blood 2009;114(9):1803-12.
2009: Hoering Antje; Crowley John; Shaughnessy John D; Hollmig Klaus; Alsayed Yazan; Szymonifka Jackie; Waheed Sarah; Nair Bijay; van Rhee Frits; Anaissie Elias; Barlogie Bart
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
Blood 2009;114(7):1299-305.
2009: Hussein Mohamad A; Bolejack Vanessa; Zonder Jeffrey A; Durie Brian G M; Jakubowiak Andrzej J; Crowley John J; Barlogie Bart
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3510-7.
2009: Tricot Guido; Kern Steven E; Barlogie Bart
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Journal of the National Cancer Institute 2009;101(13):964-6; author reply 966-7.
2009: Wang Siqing; Tricot Guido; Shi Lei; Xiong Wei; Zeng Zhaoyang; Xu Hongwei; Zangari Maurizio; Barlogie Bart; Shaughnessy John D; Zhan Fenghuang
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
Blood 2009;114(3):600-7.
2009: Nair Bijay; Shaughnessy John D; Zhou Yiming; Astrid-Cartron Marie; Qu Pingping; van Rhee Frits; Anaissie Elias; Alsayed Yazan; Waheed Sarah; Hollmig Klaus; Szymonifka Jackie; Petty Nathan; Hoering Antje; Barlogie Bart
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Blood 2009;113(26):6572-5.
2009: Pennisi Angela; Li Xin; Ling Wen; Khan Sharmin; Gaddy Dana; Suva Larry J; Barlogie Bart; Shaughnessy John D; Aziz Nazneen; Yaccoby Shmuel
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
British journal of haematology 2009;145(6):775-87.
2009: Zhou Yiming; Nair Bijay; Shaughnessy John D; Cartron Marie-Astrid; Haessler Jeff; Anaissie Elias; van Rhee Frits; Crowley John; Barlogie Bart
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
British journal of haematology 2009;145(5):637-41.
2009: Sprynski Anne Catherine; Hose Dirk; Caillot Laurent; Réme Thierry; Shaughnessy John D; Barlogie Bart; Seckinger Anja; Moreaux Jérôme; Hundemer Michael; Jourdan Michel; Meissner Tobias; Jauch Anna; Mahtouk Karène; Kassambara Alboukadel; Bertsch Uta; Rossi Jean François; Goldschmidt Hartmut; Klein Bernard
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
Blood 2009;113(19):4614-26.
2009: Brenne Anne-Tove; Fagerli Unn-Merete; Shaughnessy John D; Våtsveen Thea Kristin; Rø Torstein Baade; Hella Hanne; Zhan Fenghuang; Barlogie Bart; Sundan Anders; Børset Magne; Waage Anders
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.
European journal of haematology 2009;82(5):354-63.
2009: Morel Pierre; Duhamel Alain; Gobbi Paolo; Dimopoulos Meletios A; Dhodapkar Madhav V; McCoy Jason; Crowley John; Ocio Enrique M; Garcia-Sanz Ramon; Treon Steven P; Leblond Veronique; Kyle Robert A; Barlogie Bart; Merlini Giampaolo
International prognostic scoring system for Waldenstrom macroglobulinemia.
Blood 2009;113(18):4163-70.
2009: Qiang Ya-Wei; Hu Bo; Chen Yu; Zhong Ying; Shi Bingyin; Barlogie Bart; Shaughnessy John D
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
Blood 2009;113(18):4319-30.
2009: Hose Dirk; Rème Thierry; Meissner Tobias; Moreaux Jérôme; Seckinger Anja; Lewis Joe; Benes Vladimir; Benner Axel; Hundemer Michael; Hielscher Thomas; Shaughnessy John D; Barlogie Bart; Neben Kai; Krämer Alwin; Hillengass Jens; Bertsch Uta; Jauch Anna; De Vos John; Rossi Jean-François; Möhler Thomas; Blake Jonathon; Zimmermann Jürgen; Klein Bernard; Goldschmidt Hartmut
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
Blood 2009;113(18):4331-40.
2009: Nair Bijay; Waheed Sarah; Szymonifka Jackie; Shaughnessy John D; Crowley John; Barlogie Bart
Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols.
British journal of haematology 2009;145(1):134-7.
2009: Dhodapkar Madhav V; Hoering Antje; Gertz Morie A; Rivkin Saul; Szymonifka Jackie; Crowley John; Barlogie Bart
Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
Blood 2009;113(4):793-6.
2008: Shi Jumei; Tricot Guido; Szmania Susann; Rosen Nancy; Garg Tarun K; Malaviarachchi Priyangi A; Moreno Amberly; Dupont Bo; Hsu Katharine C; Baxter-Lowe Lee Ann; Cottler-Fox Michele; Shaughnessy John D; Barlogie Bart; van Rhee Frits
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
British journal of haematology 2008;143(5):641-53.
2008: Barlogie Bart; Epstein Joshua; Shaughnessy John D
Going with the flow, and beyond, in myeloma.
Blood 2008;112(10):3917-8.
2008: Jagannath Sundar; Barlogie Bart; Berenson James R; Siegel David S; Irwin David; Richardson Paul G; Niesvizky Ruben; Alexanian Raymond; Limentani Steven A; Alsina Melissa; Esseltine Dixie-Lee; Anderson Kenneth C
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
British journal of haematology 2008;143(4):537-40.
2008: Tricot Guido; Barlogie Bart; Zangari Maurizio; van Rhee Frits; Hoering Antje; Szymonifka Jackie; Cottler-Fox Michele
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
Haematologica 2008;93(11):1739-42.
2008: Xiong Wei; Wu Xiaosong; Starnes Sarah; Johnson Sarah K; Haessler Jeff; Wang Siqing; Chen Lijuan; Barlogie Bart; Shaughnessy John D; Zhan Fenghuang
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
Blood 2008;112(10):4235-46.
2008: Barlogie Bart; van Rhee Frits; Shaughnessy John D; Epstein Joshua; Yaccoby Shmuel; Pineda-Roman Mauricio; Hollmig Klaus; Alsayed Yazan; Hoering Antje; Szymonifka Jackie; Anaissie Elias; Petty Nathan; Kumar Naveen S; Srivastava Geetika; Jenkins Bonnie; Crowley John; Zeldis Jerome B
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Blood 2008;112(8):3122-5.
2008: Barlogie Bart; Pineda-Roman Mauricio; van Rhee Frits; Haessler Jeff; Anaissie Elias; Hollmig Klaus; Alsayed Yazan; Waheed Sarah; Petty Nathan; Epstein Joshua; Shaughnessy John D; Tricot Guido; Zangari Maurizio; Zeldis Jerome; Barer Sol; Crowley John
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Blood 2008;112(8):3115-21.
2008: Barlogie Bart; Shaughnessy John D; Crowley John
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2.
The New England journal of medicine 2008;359(13):1410.
2008: Burington Bart; Barlogie Bart; Zhan Fenghuang; Crowley John; Shaughnessy John D
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4821-9.
2008: van Rhee Frits; Dhodapkar Madhav; Shaughnessy John D; Anaissie Elias; Siegel David; Hoering Antje; Zeldis Jerome; Jenkins Bonnie; Singhal Seema; Mehta Jayesh; Crowley John; Jagannath Sundar; Barlogie Bart
First thalidomide clinical trial in multiple myeloma: a decade.
Blood 2008;112(4):1035-8.
2008: Barlogie Bart; Shaughnessy John D; Crowley John
Duration of survival in patients with myeloma treated with thalidomide.
The New England journal of medicine 2008;359(2):210-2.
2008: Lynch Henry T; Ferrara Kelly; Barlogie Bart; Coleman Elizabeth A; Lynch Jane F; Weisenburger Dennis; Sanger Warren; Watson Patrice; Nipper Henry; Witt Vinetta; Thomé Stephan
Familial myeloma.
The New England journal of medicine 2008;359(2):152-7.
2008: Barlogie Bart; Anaissie Elias; Haessler Jeffrey; van Rhee Fritz; Pineda-Roman Mauricio; Hollmig Klaus; Alsayed Yazan; Epstein Joshua; Shaughnessy John D; Crowley John
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.
Cancer 2008;113(2):355-9.
2008: Pineda-Roman M; Zangari M; van Rhee F; Anaissie E; Szymonifka J; Hoering A; Petty N; Crowley J; Shaughnessy J; Epstein J; Barlogie B
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(7):1419-27.
2008: Gabrea Ana; Martelli Maria Luisa; Qi Ying; Roschke Anna; Barlogie Bart; Shaughnessy John D; Sawyer Jeffrey R; Kuehl W Michael
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
Genes, chromosomes & cancer 2008;47(7):573-90.
2008: Qiang Ya-Wei; Chen Yu; Stephens Owen; Brown Nathan; Chen Bangzheng; Epstein Joshua; Barlogie Bart; Shaughnessy John D
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
Blood 2008;112(1):196-207.
2008: Barlogie Bart; Haessler Jeff; Pineda-Roman Mauricio; Anaissie Elias; van Rhee Frits; Kiwan Elias; Steward Douglas; Gurley Jennifer; Jenkins Bonnie; Crowley John
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
Cancer 2008;112(12):2720-5.
2008: Coleman Elizabeth A; Coon Sharon K; Kennedy Robert L; Lockhart Kimberly D; Stewart Carol B; Anaissie Elias J; Barlogie Bart
Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma.
Oncology nursing forum 2008;35(3):E53-61.
2008: Hsi Eric D; Steinle Roxanne; Balasa Balaji; Szmania Susann; Draksharapu Aparna; Shum Benny P; Huseni Mahrukh; Powers David; Nanisetti Amulya; Zhang Yin; Rice Audie G; van Abbema Anne; Wong Melanie; Liu Gao; Zhan Fenghuang; Dillon Myles; Chen Shihao; Rhodes Susan; Fuh Franklin; Tsurushita Naoya; Kumar Shankar; Vexler Vladimir; Shaughnessy John D; Barlogie Bart; van Rhee Frits; Hussein Mohamad; Afar Daniel E H; Williams Marna B
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2775-84.
2008: Miceli Marisa H; Grazziutti Monica L; Woods Gail; Zhao Weizhi; Kocoglu Mehmet H; Barlogie Bart; Anaissie Elias
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(9):1412-22.
2008: Zangari Maurizio; van Rhee Frits; Anaissie Elias; Pineda-Roman Mauricio; Haessler Jeff; Crowley John; Barlogie Bart
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
British journal of haematology 2008;141(4):433-44.
2008: Pineda-Roman Mauricio; Barlogie Bart; Anaissie Elias; Zangari Maurizio; Bolejack Vanessa; van Rhee Frits; Tricot Guido; Crowley John
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Cancer 2008;112(8):1754-64.
2008: Qiang Ya-Wei; Barlogie Bart; Rudikoff Stuart; Shaughnessy John D
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Bone 2008;42(4):669-80.
2008: Ludwig Heinz; Durie Brian G M; Bolejack Vanessa; Turesson Ingemar; Kyle Robert A; Blade Joan; Fonseca Rafael; Dimopoulos Meletios; Shimizu Kazuyuki; San Miguel Jesus; Westin Jan; Harousseau Jean-Luc; Beksac Meral; Boccadoro Mario; Palumbo Antonio; Barlogie Bart; Shustik Chaim; Cavo Michele; Greipp Philip R; Joshua Douglas; Attal Michel; Sonneveld Pieter; Crowley John
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
Blood 2008;111(8):4039-47.
2008: Arzoumanian V; Hoering A; Sawyer J; van Rhee F; Bailey C; Gurley J; Shaughnessy J D; Anaissie E; Crowley J; Barlogie B
Suppression of abnormal karyotype predicts superior survival in multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(4):850-5.
2008: Tian Erming; Landowski Terry H; Stephens Owen W; Yaccoby Shmuel; Barlogie Bart; Shaughnessy John D
Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma.
Molecular cancer therapeutics 2008;7(3):500-9.
2008: Pineda-Roman Mauricio; Zangari Maurizio; Haessler Jeff; Anaissie Elias; Tricot Guido; van Rhee Frits; Crowley John; Shaughnessy John D; Barlogie Bart
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
British journal of haematology 2008;140(6):625-34.
2008: Matsui Shigeyuki; Yamanaka Takeharu; Barlogie Bart; Shaughnessy John D; Crowley John
Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma.
Statistics in medicine 2008;27(7):1106-20.
2008: Shi Jumei; Tricot Guido J; Garg Tarun K; Malaviarachchi Priyangi A; Szmania Susann M; Kellum Rachel E; Storrie Brian; Mulder Arend; Shaughnessy John D; Barlogie Bart; van Rhee Frits
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Blood 2008;111(3):1309-17.
2008: Gokden Neriman; Barlogie Bart; Liapis Helen
Morphologic heterogeneity of renal light-chain deposition disease.
Ultrastructural pathology 2008;32(1):17-24.
2008: Zhan Fenghuang; Barlogie Bart; Mulligan George; Shaughnessy John D; Bryant Barb
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
Blood 2008;111(2):968-9.
2008: Fagerli Unn-Merete; Holt Randi U; Holien Toril; Vaatsveen Thea K; Zhan Fenghuang; Egeberg Kjartan W; Barlogie Bart; Waage Anders; Aarset Harald; Dai Hong Yan; Shaughnessy John D; Sundan Anders; Børset Magne
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Blood 2008;111(2):806-15.
2008: Barlogie Bart; Tricot Guido; Haessler Jeff; van Rhee Frits; Cottler-Fox Michele; Anaissie Elias; Waldron James; Pineda-Roman Mauricio; Thertulien Raymond; Zangari Maurizio; Hollmig Klaus; Mohiuddin Abid; Alsayed Yazan; Hoering Antje; Crowley John; Sawyer Jeffrey
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Blood 2008;111(1):94-100.
2008: Van Ness Brian; Ramos Christine; Haznadar Majda; Hoering Antje; Haessler Jeff; Crowley John; Jacobus Susanna; Oken Martin; Rajkumar Vincent; Greipp Philip; Barlogie Bart; Durie Brian; Katz Michael; Atluri Gowtham; Fang Gang; Gupta Rohit; Steinbach Michael; Kumar Vipin; Mushlin Richard; Johnson David; Morgan Gareth
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.
BMC medicine 2008;6():26.
2007: Barlogie Bart; Anaissie Elias; van Rhee Frits; Pineda-Roman Mauricio; Zangari Maurizio; Shaughnessy John; Epstein Joshua; Crowley John
The Arkansas approach to therapy of patients with multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):761-81.
2007: Haessler Jeffrey; Shaughnessy John D; Zhan Fenghuang; Crowley John; Epstein Joshua; van Rhee Frits; Anaissie Elias; Pineda-Roman Mauricio; Zangari Maurizio; Hollmig Klaus; Mohiuddin Abid; Alsayed Yazan; Hoering Antje; Tricot Guido; Barlogie Bart
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(23):7073-9.
2007: Szmania Susann; Gnjatic Sacha; Tricot Guido; Stone Katie; Zhan Fenghuang; Moreno Amberly; Thuro Brad; Melenhorst Jos; Barrett John; Shaughnessy John; Old Lloyd J; Barlogie Bart; Brichard Vincent G; van Rhee Frits
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(8):847-54.
2007: Zangari Maurizio; Barlogie Bart; Cavallo Federica; Bolejack Vanessa; Fink Louis; Tricot Guido
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(7):595-8.
2007: Yang Yang; MacLeod Veronica; Dai Yuemeng; Khotskaya-Sample Yekaterina; Shriver Zachary; Venkataraman Ganesh; Sasisekharan Ram; Naggi Annamaria; Torri Giangiacomo; Casu Benito; Vlodavsky Israel; Suva Larry J; Epstein Joshua; Yaccoby Shmuel; Shaughnessy John D; Barlogie Bart; Sanderson Ralph D
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Blood 2007;110(6):2041-8.
2007: Annunziata Christina M; Davis R Eric; Demchenko Yulia; Bellamy William; Gabrea Ana; Zhan Fenghuang; Lenz Georg; Hanamura Ichiro; Wright George; Xiao Wenming; Dave Sandeep; Hurt Elaine M; Tan Bruce; Zhao Hong; Stephens Owen; Santra Madhumita; Williams David R; Dang Lenny; Barlogie Bart; Shaughnessy John D; Kuehl W Michael; Staudt Louis M
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Cancer cell 2007;12(2):115-30.
2007: Woods Gail; Miceli Marisa H; Grazziutti Monica L; Zhao Weizhi; Barlogie Bart; Anaissie Elias
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer.
Cancer 2007;110(4):830-4.
2007: van Rhee Frits; Bolejack Vanessa; Hollmig Klaus; Pineda-Roman Mauricio; Anaissie Elias; Epstein Joshua; Shaughnessy John D; Zangari Maurizio; Tricot Guido; Mohiuddin Abid; Alsayed Yazan; Woods Gail; Crowley John; Barlogie Bart
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Blood 2007;110(3):827-32.
2007: Barlogie Bart; Anaissie Elias; van Rhee Frits; Haessler Jeffrey; Hollmig Klaus; Pineda-Roman Mauricio; Cottler-Fox Michele; Mohiuddin Abid; Alsayed Yazan; Tricot Guido; Bolejack Vanessa; Zangari Maurizio; Epstein Joshua; Petty Nathan; Steward Douglas; Jenkins Bonnie; Gurley Jennifer; Sullivan Ellen; Crowley John; Shaughnessy John D
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
British journal of haematology 2007;138(2):176-85.
2007: Miceli Marisa H; Maertens Johan; Buvé Kristel; Grazziutti Monica; Woods Gail; Rahman Mazhar; Barlogie Bart; Anaissie Elias J
Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications.
Cancer 2007;110(1):112-20.
2007: van Rhee Frits; Crowley John; Barlogie Bart
Allografting or autografting for myeloma.
The New England journal of medicine 2007;356(25):2646-8; author reply 2646-8.
2007: Shaughnessy John D; Haessler Jeffrey; van Rhee Frits; Anaissie Elias; Pineda-Roman Mauricio; Cottler-Fox Michele; Hollmig Klaus; Zangari Maurizio; Mohiuddin Abid; Alsayed Yazan; Grazziutti Monica; Epstein Joshua; Crowley John; Barlogie Bart
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
British journal of haematology 2007;137(6):530-6.
2007: Zhan Fenghuang; Colla Simona; Wu Xiaosong; Chen Bangzheng; Stewart James P; Kuehl W Michael; Barlogie Bart; Shaughnessy John D
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
Blood 2007;109(11):4995-5001.
2007: Colla Simona; Zhan Fenghuang; Xiong Wei; Wu Xiaosong; Xu Hongwei; Stephens Owen; Yaccoby Shmuel; Epstein Joshua; Barlogie Bart; Shaughnessy John D
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
Blood 2007;109(10):4470-7.
2007: Talamo Giampaolo; Cavallo Federica; Zangari Maurizio; Barlogie Bart; Lee Choon-Kee; Pineda-Roman Mauricio; Kiwan Elias; Krishna Somashekar; Tricot Guido
Hyperammonemia and encephalopathy in patients with multiple myeloma.
American journal of hematology 2007;82(5):414-5.
2007: Spisek Radek; Kukreja Anjli; Chen Lin-Chi; Matthews Phillip; Mazumder Amitabha; Vesole David; Jagannath Sundar; Zebroski Henry A; Simpson Andrew J G; Ritter Gerd; Durie Brian; Crowley John; Shaughnessy John D; Scanlan Matthew J; Gure Ali O; Barlogie Bart; Dhodapkar Madhav V
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
The Journal of experimental medicine 2007;204(4):831-40.
2007: Gokden Neriman; Cetin Neslihan; Colakoglu Nagihan; Kumar Jayant; Abul-Ezz Sameh; Barlogie Bart; Liapis Helen; Walker Patrick D
Morphologic manifestations of combined light-chain deposition disease and light-chain cast nephropathy.
Ultrastructural pathology 2007;31(2):141-9.
2007: Walker Ronald; Barlogie Bart; Haessler Jeffrey; Tricot Guido; Anaissie Elias; Shaughnessy John D; Epstein Joshua; van Hemert Rudy; Erdem Eren; Hoering Antje; Crowley John; Ferris Ernest; Hollmig Klaus; van Rhee Frits; Zangari Maurizio; Pineda-Roman Mauricio; Mohiuddin Abid; Yaccoby Shmuel; Sawyer Jeffrey; Angtuaco Edgardo J
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(9):1121-8.
2007: Shaughnessy John D; Zhan Fenghuang; Burington Bart E; Huang Yongsheng; Colla Simona; Hanamura Ichiro; Stewart James P; Kordsmeier Bob; Randolph Christopher; Williams David R; Xiao Yan; Xu Hongwei; Epstein Joshua; Anaissie Elias; Krishna Somashekar G; Cottler-Fox Michele; Hollmig Klaus; Mohiuddin Abid; Pineda-Roman Mauricio; Tricot Guido; van Rhee Frits; Sawyer Jeffrey; Alsayed Yazan; Walker Ronald; Zangari Maurizio; Crowley John; Barlogie Bart
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Blood 2007;109(6):2276-84.
2007: Yaccoby Shmuel; Ling Wen; Zhan Fenghuang; Walker Ronald; Barlogie Bart; Shaughnessy John D
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
Blood 2007;109(5):2106-11.
2007: Dib Amel; Barlogie Bart; Shaughnessy John D; Kuehl Walter Michael
Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma.
Blood 2007;109(3):1337-8.
2007: Pineda-Roman Mauricio; Bolejack Vanessa; Arzoumanian Varant; Anaissie Elias; van Rhee Frits; Zangari Maurizio; Walker Ron; Hollmig Klaus; Shaughnessy John D; Epstein Joshua; Krishna Somashekar; Crowley John; Barlogie Bart
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
British journal of haematology 2007;136(3):393-9.
2007: Zhan Fenghuang; Barlogie Bart; Arzoumanian Varant; Huang Yongsheng; Williams David R; Hollmig Klaus; Pineda-Roman Mauricio; Tricot Guido; van Rhee Frits; Zangari Maurizio; Dhodapkar Madhav; Shaughnessy John D
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Blood 2007;109(4):1692-700.
2006: Yang Jing; Qian Jianfei; Wezeman Michele; Wang Siqing; Lin Pei; Wang Michael; Yaccoby Shmuel; Kwak Larry W; Barlogie Bart; Yi Qing
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.
Cancer cell 2006;10(4):295-307.
2006: Grazziutti M L; Dong L; Miceli M H; Krishna S G; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie E J
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Bone marrow transplantation 2006;38(7):501-6.
2006: Barlogie Bart; Tricot Guido J; van Rhee Frits; Angtuaco Edguardo; Walker Ron; Epstein Joshua; Shaughnessy John D; Jagannath Sundar; Bolejack Vanessa; Gurley Jennifer; Hoering Antje; Vesole David; Desikan Raman; Siegel David; Mehta Jayesh; Singhal Seema; Munshi Nikhil C; Dhodapkar Madhav; Jenkins Bonnie; Attal Michel; Harousseau Jean-Luc; Crowley John
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
British journal of haematology 2006;135(2):158-64.
2006: Zhan Fenghuang; Huang Yongsheng; Colla Simona; Stewart James P; Hanamura Ichiro; Gupta Sushil; Epstein Joshua; Yaccoby Shmuel; Sawyer Jeffrey; Burington Bart; Anaissie Elias; Hollmig Klaus; Pineda-Roman Mauricio; Tricot Guido; van Rhee Frits; Walker Ronald; Zangari Maurizio; Crowley John; Barlogie Bart; Shaughnessy John D
The molecular classification of multiple myeloma.
Blood 2006;108(6):2020-8.
2006: Hanamura Ichiro; Stewart James P; Huang Yongsheng; Zhan Fenghuang; Santra Madhumita; Sawyer Jeffrey R; Hollmig Klaus; Zangarri Maurizio; Pineda-Roman Mauricio; van Rhee Frits; Cavallo Federica; Burington Bart; Crowley John; Tricot Guido; Barlogie Bart; Shaughnessy John D
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
Blood 2006;108(5):1724-32.
2006: Elice Francesca; Fink Louis; Tricot Guido; Barlogie Bart; Zangari Maurizio
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
British journal of haematology 2006;134(4):399-405.
2006: Talamo Giampaolo; Cavallo Federica; Zangari Maurizio; Barlogie Bart; Lee Choon-Kee; Pineda-Roman Mauricio; Kiwan Elias; Krishna Somashekar; Tricot Guido
Clinical and biological features of multiple myeloma involving the gastrointestinal system.
Haematologica 2006;91(7):964-7.
2006: Jagannath Sundar; Richardson Paul G; Barlogie Bart; Berenson James R; Singhal Seema; Irwin David; Srkalovic Gordan; Schenkein David P; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Haematologica 2006;91(7):929-34.
2006: Zonder Jeffrey A; Barlogie Bart; Durie Brian G M; McCoy Jason; Crowley John; Hussein Mohamad A
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Blood 2006;108(1):403; author reply 404.
2006: Richardson Paul G; Briemberg Hannah; Jagannath Sundar; Wen Patrick Y; Barlogie Bart; Berenson James; Singhal Seema; Siegel David S; Irwin David; Schuster Michael; Srkalovic Gordan; Alexanian Raymond; Rajkumar S Vincent; Limentani Steven; Alsina Melissa; Orlowski Robert Z; Najarian Kevin; Esseltine Dixie; Anderson Kenneth C; Amato Anthony A
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
2006: Barlogie Bart; Zangari Maurizio; Bolejack Vanessa; Hollmig Klaus; Anaissie Elias; van Rhee Frits; Pineda-Roman Mauricio; Mohiuddin Abid; Crowley John; Tricot Guido
Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma.
Clinical lymphoma & myeloma 2006;6(6):469-74.
2006: Miceli M H; Dong L; Grazziutti M L; Fassas A; Thertulien R; Van Rhee F; Barlogie B; Anaissie E J
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.
Bone marrow transplantation 2006;37(9):857-64.
2006: Carrasco Daniel R; Tonon Giovanni; Huang Yongsheng; Zhang Yunyu; Sinha Raktim; Feng Bin; Stewart James P; Zhan Fenghuang; Khatry Deepak; Protopopova Marina; Protopopov Alexei; Sukhdeo Kumar; Hanamura Ichiro; Stephens Owen; Barlogie Bart; Anderson Kenneth C; Chin Lynda; Shaughnessy John D; Brennan Cameron; Depinho Ronald A
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Cancer cell 2006;9(4):313-25.
2006: Ge Yun; Zhan Fenghuang; Barlogie Bart; Epstein Joshua; Shaughnessy John; Yaccoby Shmuel
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
British journal of haematology 2006;133(1):83-92.
2006: Barlogie Bart; Tricot Guido; Rasmussen Erik; Anaissie Elias; van Rhee Frits; Zangari Maurizio; Fassas Athanasios; Hollmig Klaus; Pineda-Roman Mauricio; Shaughnessy John; Epstein Joshua; Crowley John
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Blood 2006;107(7):2633-8.
2006: Barlogie Bart; Tricot Guido; Anaissie Elias; Shaughnessy John; Rasmussen Erik; van Rhee Frits; Fassas Athanasios; Zangari Maurizio; Hollmig Klaus; Pineda-Roman Mauricio; Lee Choon; Talamo Giampaolo; Thertulien Raymond; Kiwan Elias; Krishna Somashekar; Fox Michele; Crowley John
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
The New England journal of medicine 2006;354(10):1021-30.
2006: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David H; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Anderson Kenneth C
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Cancer 2006;106(6):1316-9.
2006: Lee C-K; Zangari M; Fassas A; Thertulien R; Talamo G; Badros A; Cottler-Fox M; van Rhee F; Barlogie B; Tricot G
Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation.
Bone marrow transplantation 2006;37(5):511-5.
2006: Yaccoby Shmuel; Wezeman Michele J; Zangari Maurizio; Walker Ronald; Cottler-Fox Michele; Gaddy Danna; Ling Wen; Saha Rinku; Barlogie Bart; Tricot Guido; Epstein Joshua
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Haematologica 2006;91(2):192-9.
2006: Barlogie Bart; Kyle Robert A; Anderson Kenneth C; Greipp Philip R; Lazarus Hillard M; Hurd David D; McCoy Jason; Moore Dennis F; Dakhil Shaker R; Lanier Keith S; Chapman Robert A; Cromer Jeana N; Salmon Sydney E; Durie Brian; Crowley John C
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):929-36.
2006: Grazziutti M L; Dong L; Miceli M H; Cottler-Fox M; Krishna S G; Fassas A; van Rhee F; Barlogie B M; Anaissie E J
Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients.
Bone marrow transplantation 2006;37(4):403-9.
2006: Toor Amir A; Ramdane Ben A; Joseph Jacob; Thomas Maria; O'Hara Carl; Barlogie Bart; Walker Patrick; Joseph Lija
Cardiac nonamyloidotic immunoglobulin deposition disease.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2006;19(2):233-7.
2006: Shaughnessy John D; Barlogie Bart
Using genomics to identify high-risk myeloma after autologous stem cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(1 Suppl 1):77-80.
2006: Dib Amel; Peterson Timothy R; Raducha-Grace Laura; Zingone Adriana; Zhan Fenghuang; Hanamura Ichiro; Barlogie Bart; Shaughnessy John; Kuehl W Michael
Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.
Cell division 2006;1():23.
2005: Lonial Sagar; Waller Edmund K; Richardson Paul G; Jagannath Sundar; Orlowski Robert Z; Giver Cynthia R; Jaye David L; Francis Dixil; Giusti Sara; Torre Claire; Barlogie Bart; Berenson James R; Singhal Seema; Schenkein David P; Esseltine Dixie-Lee W; Anderson Jessica; Xiao Hugh; Heffner Leonard T; Anderson Kenneth C;
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood 2005;106(12):3777-84.
2005: Fassas Athanasios B-T; Kiwan Elias; Roberts Jennifer; Burr Tammy; Tricot Guido; Anaissie Elias; Barlogie Bart
Metronomic chemoimmunotherapy in a patient with refractory Waldenstrom's macroglobulinemia.
Leukemia & lymphoma 2005;46(11):1675-7.
2005: Batchu Ramesh B; Moreno Amberly M; Szmania Susann M; Bennett Grant; Spagnoli Guilio C; Ponnazhagan Selvarangan; Barlogie Bart; Tricot Guido; van Rhee Frits
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Cancer research 2005;65(21):10041-9.
2005: Berenson James R; Jagannath Sundar; Barlogie Bart; Siegel David T; Alexanian Raymond; Richardson Paul G; Irwin David; Alsina Melissa; Rajkumar S Vincent; Srkalovic Gordon; Singhal Seema; Limentani Steven; Niesvizky Ruben; Esseltine Dixie L; Trehu Elizabeth; Schenkein David P; Anderson Kenneth
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
2005: Mahfouz T; Miceli M H; Saghafifar F; Stroud S; Jones-Jackson L; Walker R; Grazziutti M L; Purnell G; Fassas A; Tricot G; Barlogie B; Anaissie E
18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7857-63.
2005: Richardson Paul Gerard Guy; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Hideshima Teru; Xiao Hugh; Esseltine Dixie; Schenkein David; Anderson Kenneth C;
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
2005: Zangari Maurizio; Esseltine Dixie; Lee Choon-Kee; Barlogie Bart; Elice Francesca; Burns Michael J; Kang Seung-Hee; Yaccoby Shmuel; Najarian Kevin; Richardson Paul; Sonneveld Peter; Tricot Guido
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
British journal of haematology 2005;131(1):71-3.
2005: Suzuki Atsushi; Iida Shinsuke; Kato-Uranishi Miyuki; Tajima Emi; Zhan Fenghuang; Hanamura Ichiro; Huang Yongsheng; Ogura Tsutomu; Takahashi Satoru; Ueda Ryuzo; Barlogie Bart; Shaughnessy John; Esumi Hiroyasu
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
Oncogene 2005;24(46):6936-44.
2005: Barlogie Bart
The role of transplant in multiple myeloma.
Clinical advances in hematology & oncology : H&O 2005;3(8):604-6.
2005: Fassas A B-T; Miceli M H; Grazzlutti M; Dong L; Barlogie B; Anaissie E
Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation.
Leukemia & lymphoma 2005;46(8):1159-61.
2005: Kamble R; Wilson C S; Fassas A; Desikan R; Siegel D S; Tricot G; Anderson P; Sawyer J; Anaissie E; Barlogie B
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome.
Leukemia & lymphoma 2005;46(8):1137-42.
2005: Neelapu S S; Munshi N C; Jagannath S; Watson T M; Pennington R; Reynolds C; Barlogie B; Kwak L W
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Bone marrow transplantation 2005;36(4):315-23.
2005: Talamo Giampaolo; Angtuaco Edgardo; Walker Ronald C; Dong Li; Miceli Marisa H; Zangari Maurizio; Tricot Guido; Barlogie Bart; Anaissie Elias
Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5217-23.
2005: Bergsagel P Leif; Kuehl W Michael; Zhan Fenghuang; Sawyer Jeffrey; Barlogie Bart; Shaughnessy John
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Blood 2005;106(1):296-303.
2005: Greipp Philip R; San Miguel Jesus; Durie Brian G M; Crowley John J; Barlogie Bart; Bladé Joan; Boccadoro Mario; Child J Anthony; Avet-Loiseau Herve; Kyle Robert A; Lahuerta Juan J; Ludwig Heinz; Morgan Gareth; Powles Raymond; Shimizu Kazuyuki; Shustik Chaim; Sonneveld Pieter; Tosi Patrizia; Turesson Ingemar; Westin Jan
International staging system for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3412-20.
2005: Jagannath Sundar; Barlogie Bart; Berenson James R; Singhal Seema; Alexanian Raymond; Srkalovic Gordan; Orlowski Robert Z; Richardson Paul G; Anderson Jessica; Nix Darrell; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
2005: Fassas Athanasios; Barlogie Bart; Feusner James; Kay Neil E; Wingard John R
Highlights from the 46 th annual meeting of the American Society of Hematology.
Clinical advances in hematology & oncology : H&O 2005;3(2):111-6.
2005: Fassas A; Shaughnessy J; Barlogie B
Cure of myeloma: hype or reality?
Bone marrow transplantation 2005;35(3):215-24.
2005: Sawyer Jeffrey R; Tricot Guido; Lukacs Janet L; Binz Regina Lichti; Tian Erming; Barlogie Bart; Shaughnessy John
Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q.
Genes, chromosomes & cancer 2005;42(1):95-106.
2005: Szmania S; Yi Q; Cottler-Fox M; Rosen N A; Freeman J; Kordsmeier B J; Moreno A; Shi J; Barlogie B; Tricot G; van Rhee F
Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation.
Cytotherapy 2005;7(4):374-84.
2005: Shaughnessy John; Zhan Fenghuang; Barlogie Barthel; Stewart A K
Gene expression profiling and multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):537-52.
2004: Dhodapkar Madhav V; Hussein Mohamad A; Rasmussen Erik; Solomon Alan; Larson Richard A; Crowley John J; Barlogie Bart;
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.
Blood 2004;104(12):3520-6.
2004: Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson P G; Niesvizky R; Alexanian R; Limentani S A; Alsina M; Adams J; Kauffman M; Esseltine D-L; Schenkein D P; Anderson K C
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
2004: Zangari Maurizio; Barlogie Bart; Anaissie Elias; Saghafifar Fariba; Eddlemon Paul; Jacobson Joth; Lee Choon-Kee; Thertulien Raymond; Talamo Giampaolo; Thomas Teri; Van Rhee Frits; Fassas Athanasios; Fink Louis; Tricot Guido
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
British journal of haematology 2004;126(5):715-21.
2004: Herrera Guillermo A; Joseph Lija; Gu Xin; Hough Aubrey; Barlogie Bart
Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia.
Archives of pathology & laboratory medicine 2004;128(8):875-9.
2004: Miceli Marisa H; Jones Jackson Laurie B; Walker Ronald C; Talamo Giampaolo; Barlogie Bart; Anaissie Elias J
Diagnosis of infection of implantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography.
Nuclear medicine communications 2004;25(8):813-8.
2004: Maxwell Christopher A; Rasmussen Erik; Zhan Fenghuang; Keats Jonathan J; Adamia Sophia; Strachan Erin; Crainie Mary; Walker Ronald; Belch Andrew R; Pilarski Linda M; Barlogie Bart; Shaughnessy John; Reiman Tony
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.
Blood 2004;104(4):1151-8.
2004: Stewart James Peter; Thompson Alexander; Santra Madhumita; Barlogie Bart; Lappin Terence R J; Shaughnessy John
Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.
British journal of haematology 2004;126(1):72-6.
2004: Miceli Marisa; Atoui Rola; Walker Ronald; Mahfouz Tahsine; Mirza Nadeem; Diaz Jose; Tricot Guido; Barlogie Bart; Anaissie Elias
Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(10):1949-56.
2004: Durie Brian G M; Jacobson Joth; Barlogie Bart; Crowley John
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(10):1857-63.
2004: Miceli Marisa; Atoui Rola; Thertulien Raymond; Barlogie Bart; Anaissie Elias; Walker Ronald; Jones-Jackson Laurie
Deep septic thrombophlebitis: an unrecognized cause of relapsing bacteremia in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1529-31.
2004: Fahdi Ibrahim Elias; Gaddam Venkat; Saucedo Jorge F; Kishan Channarayapatna V; Vyas Keyur; Deneke Matthew G; Razek Hani; Thorn Brett; Bissett Joseph K; Anaissie Elias J; Barlogie Bart; Mehta Jawahar L
Bradycardia during therapy for multiple myeloma with thalidomide.
The American journal of cardiology 2004;93(8):1052-5.
2004: Tricot Guido; Barlogie Bart; Van Rhee Frits
Treatment advances in multiple myeloma.
British journal of haematology 2004;125(1):24-30.
2004: Angtuaco Edgardo J C; Fassas Athanasios B T; Walker Ronald; Sethi Rajesh; Barlogie Bart
Multiple myeloma: clinical review and diagnostic imaging.
Radiology 2004;231(1):11-23.
2004: Lee C-K; Zangari M; Barlogie B; Fassas A; van Rhee F; Thertulien R; Talamo G; Muwalla F; Anaissie E; Hollmig K; Tricot G
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.
Bone marrow transplantation 2004;33(8):823-8.
2004: Yaccoby Shmuel; Wezeman Michele J; Henderson Aminah; Cottler-Fox Michele; Yi Qing; Barlogie Bart; Epstein Joshua
Cancer and the microenvironment: myeloma-osteoclast interactions as a model.
Cancer research 2004;64(6):2016-23.
2004: Anaissie Elias J; Mahfouz Tahsine H; Aslan Turan; Pouli Anastasia; Desikan Rahman; Fassas Athanasios; Barlogie Bart
The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management.
Blood 2004;103(5):1611-7.
2004: Fonseca Rafael; Barlogie Bart; Bataille Regis; Bastard Christian; Bergsagel P Leif; Chesi Marta; Davies Faith E; Drach Johannes; Greipp Philip R; Kirsch Ilan R; Kuehl W Michael; Hernandez Jesus M; Minvielle Stephane; Pilarski Linda M; Shaughnessy John D; Stewart A Keith; Avet-Loiseau Herve
Genetics and cytogenetics of multiple myeloma: a workshop report.
Cancer research 2004;64(4):1546-58.
2004: Barlogie Bart; Shaughnessy John; Tricot Guido; Jacobson Joth; Zangari Maurizio; Anaissie Elias; Walker Ron; Crowley John
Treatment of multiple myeloma.
Blood 2004;103(1):20-32.
2004: Hardin Johanna; Waddell Michael; Page C David; Zhan Fenghuang; Barlogie Bart; Shaughnessy John; Crowley John J
Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma.
Statistical applications in genetics and molecular biology 2004;3():Article10.
2003: Tian Erming; Zhan Fenghuang; Walker Ronald; Rasmussen Erik; Ma Yupo; Barlogie Bart; Shaughnessy John D
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
The New England journal of medicine 2003;349(26):2483-94.
2003: Kelly Thomas; Miao Hua-Quan; Yang Yang; Navarro Elizabeth; Kussie Paul; Huang Yan; MacLeod Veronica; Casciano Jonathan; Joseph Lija; Zhan Fenghuang; Zangari Maurizio; Barlogie Bart; Shaughnessy John; Sanderson Ralph D
High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Cancer research 2003;63(24):8749-56.
2003: Fassas Athanasios B-T; Barlogie Bart; Ward Susan; Jagannath Sundar; Vesole David; Mattox Sandy; Siegel David; Muwalla Firas; Zangari Maurizio; Anaissie Elias; Rhee Frits Van; Thertulien Raymond; Lee Choon-Kee; Desikan Raman; Arzumanian Varant; McCoy Jason; Tricot Guido
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
British journal of haematology 2003;123(3):484-9.
2003: Chiriva-Internati Maurizio; Liu Yong; Weidanz Jon A; Grizzi Fabio; You Hong; Zhou Weiping; Bumm Klaus; Barlogie Barthel; Mehta Jawahar L; Hermonat Paul L
Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.
Blood 2003;102(9):3100-7.
2003: Barlogie Bart
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Seminars in hematology 2003;40(4 Suppl 4):33-8.
2003: Zhan Fenghuang; Barlogie Bart; Shaughnessy John
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling.
Seminars in hematology 2003;40(4):308-20.
2003: Batchu R B; Moreno A M; Szmania S; Gupta S K; Zhan F; Rosen N; Kozlowski M; Spencer T; Spagnoli G C; Shaughnessy J; Barlogie B; Tricot G; van Rhee F
High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector.
Human gene therapy 2003;14(14):1333-45.
2003: Jacobson Joth L; Hussein Mohamad A; Barlogie Bart; Durie Brian G M; Crowley John J;
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
British journal of haematology 2003;122(3):441-50.
2003: Jacobson Joth; Barlogie Bart; Shaughnessy John; Drach Johannes; Tricot Guido; Fassas Athanasios; Zangari Maurizio; Giroux Dori; Crowley John; Hough Aubrey; Sawyer Jeff
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
British journal of haematology 2003;122(3):430-40.
2003: Shaughnessy John D; Barlogie Bart
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.
Immunological reviews 2003;194():140-63.
2003: Lee Choon-Kee; Barlogie Bart; Munshi Nikhil; Zangari Maurizio; Fassas Athanasios; Jacobson Joth; van Rhee Frits; Cottler-Fox Michele; Muwalla Firas; Tricot Guido
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2732-9.
2003: Onwuazor Obiageli N; Wen Xiao-Yan; Wang Ding-Yan; Zhuang Lihua; Masih-Khan Esther; Claudio Jaimie; Barlogie Bart; Shaughnessy John D; Stewart A Keith
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.
Blood 2003;102(2):772-3.
2003: Zangari Maurizio; Saghafifar Fariba; Mehta Paulette; Barlogie Bart; Fink Louis; Tricot Guido
The blood coagulation mechanism in multiple myeloma.
Seminars in thrombosis and hemostasis 2003;29(3):275-82.
2003: Zangari Maurizio; Barlogie Bart; Thertulien Raymond; Jacobson Joth; Eddleman Paul; Fink Louis; Fassas Athanasios; Van Rhee Frits; Talamo Giampaolo; Lee Choon-Kee; Tricot Guido
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Clinical lymphoma 2003;4(1):32-5.
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
2003: Wu Kai-Da; Orme Lisa M; Shaughnessy John; Jacobson Joth; Barlogie Bart; Moore Malcolm A S
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.
Blood 2003;101(12):4982-9.
2003: Shaughnessy John; Jacobson Joth; Sawyer Jeff; McCoy Jason; Fassas Athanasios; Zhan Fenghuang; Bumm Klaus; Epstein Joshua; Anaissie Elias; Jagannath Sundar; Vesole David; Siegel David; Desikan Raman; Munshi Nikhil; Badros Ashraf; Tian Erming; Zangari Maurizio; Tricot Guido; Crowley John; Barlogie Bart
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
Blood 2003;101(10):3849-56.
2003: Xie Jin; Wang Ying; Freeman Muta E; Barlogie Bart; Yi Qing
Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.
Blood 2003;101(10):4005-12.
2003: Dhodapkar Madhav V; Jacobson Joth L; Gertz Morie A; Crowley John J; Barlogie Bart
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
Seminars in oncology 2003;30(2):220-5.
2003: Kyle Robert A; Treon Steven P; Alexanian Raymond; Barlogie Bart; Björkholm Magnus; Dhodapkar Madhav; Lister T Andrew; Merlini Giampaolo; Morel Pierre; Stone Marvin; Branagan Andrew R; Leblond Véronique
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Seminars in oncology 2003;30(2):116-20.
2003: Desikan Raman; Barlogie Bart; Sethi Rajesh; Toor Amir; Spoon Dan; Angtuaco Edward; Vanhemert Rudy; VijayaGopal Anantha; Singhal Seema; Mehta Jayesh; Jagannath Sundar; Munshi Nikhil; Zangari Maurizio; Fassas Athanassios; Tricot Guido; Anaissie Elias
Infection--an underappreciated cause of bone pain in multiple myeloma.
British journal of haematology 2003;120(6):1047-50.
2003: Santra Madhumita; Zhan Fenghuang; Tian Erming; Barlogie Bart; Shaughnessy John
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Blood 2003;101(6):2374-6.
2003: Morris Christopher L; Siegel Eric; Barlogie Bart; Cottler-Fox Michele; Lin Pei; Fassas Athanasios; Zangari Maurizio; Anaissie Elias; Tricot Guido
Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
British journal of haematology 2003;120(3):413-23.
2003: Zhan Fenghuang; Tian Erming; Bumm Klaus; Smith Ruston; Barlogie Bart; Shaughnessy John
Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.
Blood 2003;101(3):1128-40.
2003: Lee Choon Kee; Badros Ashraf; Barlogie Bart; Morris Christopher; Zangari Maurizio; Fassas Athanasios; van Rhee Frits; Cottler-Fox Michele; Jacobson Joth; Thertulien Raymond; Muwalla Firas; Mazher Syed; Anaissie Elias; Tricot Guido
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Experimental hematology 2003;31(1):73-80.
2003: Shaughnessy John; Tian Erming; Sawyer Jeffrey; McCoy Jason; Tricot Guido; Jacobson Joth; Anaissie Elias; Zangari Maurizio; Fassas Athanasios; Muwalla Firas; Morris Christopher; Barlogie Bart
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
British journal of haematology 2003;120(1):44-52.
2003: Barillé-Nion Sophie; Barlogie Bart; Bataille Régis; Bergsagel P Leif; Epstein Joshua; Fenton Robert G; Jacobson Joth; Kuehl W Michael; Shaughnessy John; Tricot Guido
Advances in biology and therapy of multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003;():248-78.
2002: Barlogie Bart; Shaughnessy John; Zangari Maurizio; Tricot Guido
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Seminars in oncology 2002;29(6 Suppl 17):26-33.
2002: Lee C-K; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Bone marrow transplantation 2002;30(12):873-8.
2002: Yaccoby Shmuel; Johnson Cherie L; Mahaffey Susan C; Wezeman Michele J; Barlogie Bart; Epstein Joshua
Antimyeloma efficacy of thalidomide in the SCID-hu model.
Blood 2002;100(12):4162-8.
2002: Fassas Athanasios B-T; Spencer Trey; Desikan Raman; Zangari Maurizio; Anaissie Elias; Barlogie Bart; Tricot Guido
Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients.
British journal of haematology 2002;119(1):164-8.
2002: Fassas Athanasios B-T; Spencer Tray; Sawyer Jeffrey; Zangari Maurizio; Lee Choon-Kee; Anaissie Elias; Muwalla Firas; Morris Christopher; Barlogie Bart; Tricot Guido
Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.
British journal of haematology 2002;118(4):1041-7.
2002: Shaughnessy John D; Barlogie Bart
Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myeloma.
International journal of hematology 2002;76 Suppl 2():59-64.
2002: Barlogie Bart; Shaughnessy John D
Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH.
International journal of hematology 2002;76 Suppl 1():337-9.
2002: Zangari Maurizio; Siegel Eric; Barlogie Bart; Anaissie Elias; Saghafifar Fariba; Fassas Athanasios; Morris Christopher; Fink Louis; Tricot Guido
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
Blood 2002;100(4):1168-71.
2002: Min Rui; Li Zhongkui; Epstein Joshua; Barlogie Bart; Yi Qing
Beta(2)-microglobulin as a negative growth regulator of myeloma cells.
British journal of haematology 2002;118(2):495-505.
2002: Chiriva-Internati Maurizio; Wang Zhiqing; Salati Emanuela; Bumm Klaus; Barlogie Bart; Lim Seah H
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma.
Blood 2002;100(3):961-5.
2002: Badros Ashraf; Morris Christopher; Zangari Maurizio; Barlogie Bart; Tricot Guido
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Leukemia & lymphoma 2002;43(6):1267-71.
2002: Yi Qing; Desikan Raman; Barlogie Bart; Munshi Nikhil
Optimizing dendritic cell-based immunotherapy in multiple myeloma.
British journal of haematology 2002;117(2):297-305.
2002: Wen Yue-Jin; Min Rui; Tricot Guido; Barlogie Bart; Yi Qing
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
Blood 2002;99(9):3280-5.
2002: Berenson James R; Crowley John J; Grogan Thomas M; Zangmeister Jeffrey; Briggs Adrienne D; Mills Glenn M; Barlogie Bart; Salmon Sydney E
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
Blood 2002;99(9):3163-8.
2002: Zangari M; Saghafifar F; Anaissie E; Badros A; Desikan R; Fassas A; Mehta P; Morris C; Toor A; Whitfield D; Siegel E; Barlogie B; Fink L; Tricot G
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2002;13(3):187-92.
2002: Fassas Athanasios B-T; Muwalla Firas; Berryman Tanya; Benramdane Riad; Joseph Lija; Anaissie Elias; Sethi Rajesh; Desikan Raman; Siegel David; Badros Ashraf; Toor Amir; Zangari Maurizio; Morris Christopher; Angtuaco Edgardo; Mathew Sajini; Wilson Carla; Hough Aubrey; Harik Sami; Barlogie Bart; Tricot Guido
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
British journal of haematology 2002;117(1):103-8.
2002: Badros Ashraf Z; Siegel Eric; Bodenner Donald; Zangari Maurizio; Zeldis Jerome; Barlogie Bart; Tricot Guido
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.
The American journal of medicine 2002;112(5):412-3.
2002: Gertz Morie A; Lacy Martha Q; Dispenzieri Angela; Cheson Bruce D; Barlogie Bart; Kyle Robert A; Palladini Giovanni; Geyer Susan M; Merlini Giampaolo
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2002;9(1):24-30.
2002: Badros Ashraf; Barlogie Bart; Siegel Eric; Cottler-Fox Michele; Zangari Maurizio; Fassas Athanasios; Morris Christopher; Anaissie Elias; Van Rhee Frits; Tricot Guido
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1295-303.
2002: Zhan Fenghuang; Hardin Johanna; Kordsmeier Bob; Bumm Klaus; Zheng Mingzhong; Tian Erming; Sanderson Ralph; Yang Yang; Wilson Carla; Zangari Maurizio; Anaissie Elias; Morris Christopher; Muwalla Firas; van Rhee Frits; Fassas Athanasios; Crowley John; Tricot Guido; Barlogie Bart; Shaughnessy John
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Blood 2002;99(5):1745-57.
2002: Weick James K; Crowley John J; Hussein Mohamed A; Moore Dennis F; Barlogie Bart;
The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.
Investigational new drugs 2002;20(1):117-21.
2002: Badros Ashraf; Tricot Guido; Toor Amir; Morris Christopher; Guo Chuanfa; Munshi Nikhil; Barlogie Bart; Cottler-Fox Michele
ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.
Transfusion 2002;42(2):205-9.
2002: Bumm Klaus; Zheng Mingzhong; Bailey Clyde; Zhan Fenghuang; Chiriva-Internati M; Eddlemon Paul; Terry Julian; Barlogie Bart; Shaughnessy John D
CGO: utilizing and integrating gene expression microarray data in clinical research and data management.
Bioinformatics (Oxford, England) 2002;18(2):327-8.
2002: Yaccoby Shmuel; Pearse Roger N; Johnson Cherie L; Barlogie Bart; Choi Yongwon; Epstein Joshua
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
British journal of haematology 2002;116(2):278-90.
2002: Tricot Guido; Spencer Trey; Sawyer Jeffrey; Spoon Dan; Desikan Raman; Fassas Athanasios; Badros Ashraf; Zangari Maurizio; Munshi Nikhil; Anaissie Elias; Toor Amir; Barlogie Bart
Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.
British journal of haematology 2002;116(1):211-7.
2002: Khassawneh Basheer Y; White Peter; Anaissie Elias J; Barlogie Barthel; Hiller F Charles
Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation.
Chest 2002;121(1):185-8.
2002: Anderson Kenneth C; Shaughnessy John D; Barlogie Bart; Harousseau Jean-Luc; Roodman G David
Multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():214-40.
2001: Barlogie B; Tricot G; Anaissie E
Thalidomide in the management of multiple myeloma.
Seminars in oncology 2001;28(6):577-82.
2001: Badros A; Barlogie B; Siegel E; Roberts J; Langmaid C; Zangari M; Desikan R; Shaver M J; Fassas A; McConnell S; Muwalla F; Barri Y; Anaissie E; Munshi N; Tricot G
Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
British journal of haematology 2001;114(4):822-9.
2001: Badros A; Barlogie B; Siegel E; Morris C; Desikan R; Zangari M; Fassas A; Anaissie E; Munshi N; Tricot G
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.
British journal of haematology 2001;114(3):600-7.
2001: Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal A V; Morris C; Toor A; Siegel E; Fink L; Tricot G
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Blood 2001;98(5):1614-5.
2001: Shaughnessy J D; Barlogie B
Developmental therapeutics for multiple myeloma--a road map for the future.
Seminars in hematology 2001;38(3):295-7.
2001: Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G
Thalidomide in the management of multiple myeloma.
Seminars in hematology 2001;38(3):250-9.
2001: Barlogie B
Introduction to therapies in multiple myeloma.
Seminars in hematology 2001;38(3):201-2.
2001: Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Blood 2001;98(2):492-4.
2001: Shaughnessy J; Gabrea A; Qi Y; Brents L; Zhan F; Tian E; Sawyer J; Barlogie B; Bergsagel P L; Kuehl M
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Blood 2001;98(1):217-23.
2001: Dhodapkar M V; Jacobson J L; Gertz M A; Rivkin S E; Roodman G D; Tuscano J M; Shurafa M; Kyle R A; Crowley J J; Barlogie B
Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Blood 2001;98(1):41-8.
2001: Badros A; Barlogie B; Morris C; Desikan R; Martin S R; Munshi N; Zangari M; Mehta J; Toor A; Cottler-Fox M; Fassas A; Anaissie E; Schichman S; Tricot G;
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.
Blood 2001;97(9):2574-9.
2001: Avva R; Vanhemert R L; Barlogie B; Munshi N; Angtuaco E J
CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities.
AJNR. American journal of neuroradiology 2001;22(4):781-5.
2001: Wilson C S; Butch A W; Lai R; Medeiros L J; Sawyer J R; Barlogie B; McCourty A; Kelly K; Brynes R K
Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.
British journal of haematology 2001;112(3):776-82.
2001: Lim S H; Badros A; Lue C; Barlogie B
Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma.
Cancer 2001;91(5):900-8.
2001: Wen Y J; Barlogie B; Yi Q
Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Blood 2001;97(6):1750-5.
2001: Chiriva-Internati M; Du J; Cannon M; Barlogie B; Yi Q
Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.
British journal of haematology 2001;112(2):410-20.
2001: Desikan K R; Tricot G; Munshi N C; Anaissie E; Spoon D; Fassas A; Toor A; Zangari M; Badros A; Morris C; Vesole D H; Siegel D; Jagannath S; Barlogie B
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.
British journal of haematology 2001;112(1):242-7.
2001: Sawyer J R; Lukacs J L; Thomas E L; Swanson C M; Goosen L S; Sammartino G; Gilliland J C; Munshi N C; Tricot G; Shaughnessy J D; Barlogie B
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma.
British journal of haematology 2001;112(1):167-74.
2000: Shaughnessy J; Tian E; Sawyer J; Bumm K; Landes R; Badros A; Morris C; Tricot G; Epstein J; Barlogie B
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.
Blood 2000;96(4):1505-11.
2000: Aguayo A; O'Brien S; Keating M; Manshouri T; Gidel C; Barlogie B; Beran M; Koller C; Kantarjian H; Albitar M
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.
Blood 2000;96(2):768-70.
2000: Desikan K R; Dhodapkar M V; Barlogie B
Waldenström's macroglobulinemia.
Current treatment options in oncology 2000;1(2):97-103.
2000: Desikan R; Barlogie B; Sawyer J; Ayers D; Tricot G; Badros A; Zangari M; Munshi N C; Anaissie E; Spoon D; Siegel D; Jagannath S; Vesole D; Epstein J; Shaughnessy J; Fassas A; Lim S; Roberson P; Crowley J
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Blood 2000;95(12):4008-10.
2000: Desikan K R; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole D H; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
Bone marrow transplantation 2000;25(5):483-7.
1999: Aguayo A; Estey E; Kantarjian H; Mansouri T; Gidel C; Keating M; Giles F; Estrov Z; Barlogie B; Albitar M
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Blood 1999;94(11):3717-21.
1999: Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
Antitumor activity of thalidomide in refractory multiple myeloma.
The New England journal of medicine 1999;341(21):1565-71.
1999: Munshi N C; Barlogie B; Desikan K R; Wilson C
Novel approaches in myeloma therapy.
Seminars in oncology 1999;26(5 Suppl 13):28-34.
1999: Aslan T; Fassas A B; Desikan R; Siegel D; Munshi N; Mehta J; Singhal S; Barlogie B; Anaissie E
Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy.
Bone marrow transplantation 1999;24(5):505-9.
1999: Vesole D H; Crowley J J; Catchatourian R; Stiff P J; Johnson D B; Cromer J; Salmon S E; Barlogie B
High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2173-9.
1999: Singhal S; Mehta J; Desikan K; Siegel D; Singh J; Munshi N; Spoon D; Anaissie E; Ayers D; Barlogie B
Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy.
Bone marrow transplantation 1999;24(1):13-7.
1999: Desikan R; Dhodapkar M; Siegel D; Fassas A; Singh J; Singhal S; Mehta J; Vesole D; Tricot G; Jagannath S; Anaissie E; Barlogie B; Munshi N C
High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia.
British journal of haematology 1999;105(4):993-6.
1999: Fassas A B; Desikan K R; Siegel D; Golper T A; Munshi N C; Barlogie B; Tricot G
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma.
British journal of haematology 1999;105(4):938-41.
1999: Feinman R; Koury J; Thames M; Barlogie B; Epstein J; Siegel D S
Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.
Blood 1999;93(9):3044-52.
1999: Fassas A; Jagannath S; Desikan K R; Shah H R; Shaver R; Waldron J; Munshi N C; Barlogie B; Tricot G
Lymphomatoid granulomatosis following autologous stem cell transplantation.
Bone marrow transplantation 1999;23(1):79-81.
1999: Barlogie B; Jagannath S; Desikan K R; Mattox S; Vesole D; Siegel D; Tricot G; Munshi N; Fassas A; Singhal S; Mehta J; Anaissie E; Dhodapkar D; Naucke S; Cromer J; Sawyer J; Epstein J; Spoon D; Ayers D; Cheson B; Crowley J
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Blood 1999;93(1):55-65.
1999: Siegel D S; Desikan K R; Mehta J; Singhal S; Fassas A; Munshi N; Anaissie E; Naucke S; Ayers D; Spoon D; Vesole D; Tricot G; Barlogie B
Age is not a prognostic variable with autotransplants for multiple myeloma.
Blood 1999;93(1):51-4.
1999: Shaughnessy J; Barlogie B
Chromosome 13 deletion in myeloma.
Current topics in microbiology and immunology 1999;246():199-203.
1998: Dhodapkar M V; Weinstein R; Tricot G; Jagannath S; Parfitt A M; Manolagas S C; Barlogie B
Biologic and therapeutic determinants of bone mineral density in multiple myeloma.
Leukemia & lymphoma 1998;32(1-2):121-7.
1998: Sawyer J R; Lukacs J L; Munshi N; Desikan K R; Singhal S; Mehta J; Siegel D; Shaughnessy J; Barlogie B
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.
Blood 1998;92(11):4269-78.
1998: Dhodapkar M V; Singh J; Mehta J; Fassas A; Desikan K R; Perlman M; Munshi N C; Barlogie B
Anti-myeloma activity of pamidronate in vivo.
British journal of haematology 1998;103(2):530-2.
1998: Rudnicki S A; Harik S I; Dhodapkar M; Barlogie B; Eidelberg D
Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment.
Neurology 1998;51(4):1210-3.
1998: Yaccoby S; Barlogie B; Epstein J
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
Blood 1998;92(8):2908-13.
1998: Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Bone marrow transplantation 1998;21(11):1101-7.
1998: Tricot G; Gazitt Y; Leemhuis T; Jagannath S; Desikan K R; Siegel D; Fassas A; Tindle S; Nelson J; Juttner C; Tsukamoto A; Hallagan J; Atkinson K; Reading C; Hoffman R; Barlogie B
Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.
Blood 1998;91(12):4489-95.
1998: Mehta J; Tricot G; Jagannath S; Ayers D; Singhal S; Siegel D; Desikan K; Munshi N; Fassas A; Mattox S; Vesole D; Crowley J; Barlogie B
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
Bone marrow transplantation 1998;21(9):887-92.
1998: Zent C S; Wilson C S; Tricot G; Jagannath S; Siegel D; Desikan K R; Munshi N; Bracy D; Barlogie B; Butch A W
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.
Blood 1998;91(9):3518-23.
1998: Desikan K R; Barlogie B; Jagannath S; Vesole D H; Siegel D; Fassas A; Munshi N; Singhal S; Mehta J; Tindle S; Nelson J; Bracy D; Mattox S; Tricot G
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1547-53.
1998: Dhodapkar M V; Abe E; Theus A; Lacy M; Langford J K; Barlogie B; Sanderson R D
Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
Blood 1998;91(8):2679-88.
1998: Sawyer J R; Tricot G; Mattox S; Jagannath S; Barlogie B
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.
Blood 1998;91(5):1732-41.
1998: Desikan K R; Jagannath S; Siegel D; Nelson J; Bracy D; Barlogie B; Tricot G
Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.
Leukemia & lymphoma 1998;28(5-6):501-8.
1998: Barlogie B; Jagannath S; Tricot G; Desikan K R; Fassas A; Siegel D
Advances in the treatment of multiple myeloma.
Advances in internal medicine 1998;43():279-320.
1997: Barlogie B
Advances in therapy of multiple myeloma: lessons from acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2605-13.
1997: Dhodapkar M V; Kelly T; Theus A; Athota A B; Barlogie B; Sanderson R D
Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.
British journal of haematology 1997;99(2):368-71.
1997: Dhodapkar M V; Jagannath S; Vesole D; Munshi N; Naucke S; Tricot G; Barlogie B
Treatment of AL-amyloidosis with dexamethasone plus alpha interferon.
Leukemia & lymphoma 1997;27(3-4):351-6.
1997: Desikan K R; Dhodapkar M V; Hough A; Waldron T; Jagannath S; Siegel D; Barlogie B; Tricot G
Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.
Leukemia & lymphoma 1997;27(3-4):315-9.
1997: Jagannath S; Vesole D H; Zhang M; Desikan K R; Copeland N; Jagannath M; Bracy D; Jones R; Crowley J; Tricot G; Barlogie B
Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma.
Bone marrow transplantation 1997;20(6):445-50.
1997: Singhal S; Mehta J; Barlogie B
Advances in the treatment of multiple myeloma.
Current opinion in hematology 1997;4(4):291-7.
1997: Mehta J; Tricot G; Jagannath S; Desikan K R; Siegel D; Singhal S; Munshi N; Vesole D; Mattox S; Bracy D; Barlogie B
High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant.
Bone marrow transplantation 1997;20(2):113-6.
1997: Guba S C; Vesole D H; Jagannath S; Bracy D; Barlogie B; Tricot G
Peripheral stem cell mobilization and engraftment in patients over age 60.
Bone marrow transplantation 1997;20(1):1-3.
1997: Tricot G; Sawyer J R; Jagannath S; Desikan K R; Siegel D; Naucke S; Mattox S; Bracy D; Munshi N; Barlogie B
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2659-66.
1997: Munshi N C; Govindarajan R; Drake R; Ding L M; Iyer R; Saylors R; Kornbluth J; Marcus S; Chiang Y; Ennist D; Kwak L; Reynolds C; Tricot G; Barlogie B
Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir.
Blood 1997;89(4):1334-40.
1997: Barlogie B; Jagannath S; Vesole D H; Naucke S; Cheson B; Mattox S; Bracy D; Salmon S; Jacobson J; Crowley J; Tricot G
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
Blood 1997;89(3):789-93.
1997: Siegel D S; Terry J A; Koury J; Barlogie B; Epstein J; Feinman R
Myc/max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells.
Current topics in microbiology and immunology 1997;224():257-60.
1996: Govindarajan R; Jagannath S; Flick J T; Vesole D H; Sawyer J; Barlogie B; Tricot G
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.
British journal of haematology 1996;95(2):349-53.
1996: Vesole D H; Tricot G; Jagannath S; Desikan K R; Siegel D; Bracy D; Miller L; Cheson B; Crowley J; Barlogie B
Autotransplants in multiple myeloma: what have we learned?
Blood 1996;88(3):838-47.
1996: Tricot G; Alberts D S; Johnson C; Roe D J; Dorr R T; Bracy D; Vesole D H; Jagannath S; Meyers R; Barlogie B
Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):947-52.
1996: Tricot G; Jagannath S; Vesole D H; Bracy D; Desikan K R; Siegel D; Barlogie B
Hematopoietic stem cell transplants for multiple myeloma.
Leukemia & lymphoma 1996;22(1-2):25-36.
1996: Tricot G; Vesole D H; Jagannath S; Hilton J; Munshi N; Barlogie B
Graft-versus-myeloma effect: proof of principle.
Blood 1996;87(3):1196-8.
1996: Gazitt Y; Tian E; Barlogie B; Reading C L; Vesole D H; Jagannath S; Schnell J; Hoffman R; Tricot G
Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.
Blood 1996;87(2):805-11.
1996: Tricot G J; Naucke S; Vaught L; Vesole D; Jagannath S; Barlogie B
Is the risk of multiple myeloma increased in patients with silicone implants?
Current topics in microbiology and immunology 1996;210():357-9.
1995: Epstein J; Hoover R; Kornbluth J; Barlogie B
Biological aspects of multiple myeloma.
Baillière's clinical haematology 1995;8(4):721-34.
1995: Tricot G; Barlogie B; Jagannath S; Bracy D; Mattox S; Vesole D H; Naucke S; Sawyer J R
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.
Blood 1995;86(11):4250-6.
1995: Sawyer J R; Waldron J A; Jagannath S; Barlogie B
Cytogenetic findings in 200 patients with multiple myeloma.
Cancer genetics and cytogenetics 1995;82(1):41-9.
1995: Tricot G; Jagannath S; Vesole D H; Crowley J; Barlogie B
Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.
Bone marrow transplantation 1995;16(1):7-11.
1995: Gazitt Y; Reading C C; Hoffman R; Wickrema A; Vesole D H; Jagannath S; Condino J; Lee B; Barlogie B; Tricot G
Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.
Blood 1995;86(1):381-9.
1995: Hoover R G; Lary C; Page R; Travis P; Owens R; Flick J; Kornbluth J; Barlogie B
Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.
The Journal of clinical investigation 1995;95(1):241-7.
1995: Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
Blood 1995;85(2):588-96.
1995: Barlogie B; Hoover R; Epstein J
Multiple myeloma--recent developments in molecular and cellular biology.
Current topics in microbiology and immunology 1995;194():37-41.
1994: Hardin J; MacLeod S; Grigorieva I; Chang R; Barlogie B; Xiao H; Epstein J
Interleukin-6 prevents dexamethasone-induced myeloma cell death.
Blood 1994;84(9):3063-70.
1994: Vesole D H; Jagannath S; Glenn L D; Barlogie B
Effect of low-dose granulocyte-macrophage colony-stimulating factor (LD-GM-CSF) on platelet transfusion-dependent thrombocytopenia.
American journal of hematology 1994;47(3):203-7.
1994: Dao D D; Sawyer J R; Epstein J; Hoover R G; Barlogie B; Tricot G
Deletion of the retinoblastoma gene in multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(8):1280-4.
1994: Vesole D H; Barlogie B; Jagannath S; Cheson B; Tricot G; Alexanian R; Crowley J
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.
Blood 1994;84(3):950-6.
1994: Beck J T; Hsu S M; Wijdenes J; Bataille R; Klein B; Vesole D; Hayden K; Jagannath S; Barlogie B
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.
The New England journal of medicine 1994;330(9):602-5.
1994: Alexanian R; Dimopoulos M; Smith T; Delasalle K; Barlogie B; Champlin R
Limited value of myeloablative therapy for late multiple myeloma.
Blood 1994;83(2):512-6.
1994: Barlogie B; Jagannath S; Vesole D; Tricot G
Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma.
Journal of hematotherapy 1994;3(2):149-53.
1993: Hsu S M; Waldron J A; Xie S S; Barlogie B
Expression of interleukin-6 in Castleman's disease.
Human pathology 1993;24(8):833-9.
1993: Barlogie B
Hemopoietic stem cell transplant for multiple myeloma (MM).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(7):1095.
1993: Vesole D H; Jagannath S; Glenn L; Barlogie B
Autotransplantation in multiple myeloma.
Hematology/oncology clinics of North America 1993;7(3):613-30.
1993: Hsu S M; Waldron J A; Fink L; King C; Xie S S; Mansouri A; Barlogie B
Pathogenic significance of interleukin-6 in angioimmunoblastic lymphadenopathy-type T-cell lymphoma.
Human pathology 1993;24(2):126-31.
1992: Barlogie B; Gale R P
Multiple myeloma and chronic lymphocytic leukemia: parallels and contrasts.
The American journal of medicine 1992;93(4):443-50.
1992: Jagannath S; Vesole D H; Glenn L; Crowley J; Barlogie B
Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.
Blood 1992;80(7):1666-72.
1992: Alexanian R; Dimopoulos M A; Delasalle K; Barlogie B
Primary dexamethasone treatment of multiple myeloma.
Blood 1992;80(4):887-90.
1992: Jagannath S; Barlogie B
Autologous bone marrow transplantation for multiple myeloma.
Hematology/oncology clinics of North America 1992;6(2):437-49.
1992: Barlogie B
Pathophysiology of human multiple myeloma--recent advances and future directions.
Current topics in microbiology and immunology 1992;182():245-50.
1992: Barlogie B; Jagannath S
Autotransplants in myeloma.
Bone marrow transplantation 1992;10 Suppl 1():37-44.
1991: Dimopoulos M A; Barlogie B; Smith T L; Alexanian R
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
Annals of internal medicine 1991;115(12):931-5.
1991: Barlogie B; Gahrton G
Bone marrow transplantation in multiple myeloma.
Bone marrow transplantation 1991;7(2):71-9.
1991: el-Naggar A K; Batsakis J G; Teague K; Garnsey L; Barlogie B
Single- and double-stranded RNA measurements by flow cytometry in solid neoplasms.
Cytometry 1991;12(4):330-5.
1990: Jagannath S; Barlogie B; Dicke K; Alexanian R; Zagars G; Cheson B; Lemaistre F C; Smallwood L; Pruitt K; Dixon D O
Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
Blood 1990;76(9):1860-6.
1990: Alexanian R; Barlogie B
New treatment strategies for multiple myeloma.
American journal of hematology 1990;35(3):194-8.
1990: Barlogie B; Jagannath S; Dixon D O; Cheson B; Smallwood L; Hendrickson A; Purvis J D; Bonnem E; Alexanian R
High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.
Blood 1990;76(4):677-80.
1990: Kantarjian H M; Walters R S; Keating M J; Smith T L; O'Brien S; Estey E H; Huh Y O; Spinolo J; Dicke K; Barlogie B
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):994-1004.
1990: Ventura G J; Barlogie B; Hester J P; Yau J C; LeMaistre C F; Wallerstein R O; Spinolo J A; Dicke K A; Horwitz L H; Alexanian R
High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.
Bone marrow transplantation 1990;5(4):265-8.
1990: Selvanayagam P; Strong L C; Saunders G F; Barlogie B
A rare BclI RFLP in the putative oncogene bcl-1 locus.
Nucleic acids research 1990;18(6):1665.
1990: Alexanian R; Barlogie B; Tucker S
VAD-based regimens as primary treatment for multiple myeloma.
American journal of hematology 1990;33(2):86-9.
1989: Barlogie B; Velasquez W S; Alexanian R; Cabanillas F
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(10):1514-7.
1989: Keating M J; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich E J; McCredie K B
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Blood 1989;74(1):19-25.
1989: Barlogie B; Epstein J; Selvanayagam P; Alexanian R
Plasma cell myeloma--new biological insights and advances in therapy.
Blood 1989;73(4):865-79.
1988: Barlogie B; Alexanian R; Smallwood L; Cheson B; Dixon D; Dicke K; Cabanillas F
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
Blood 1988;72(6):2015-9.
1988: Kantarjian H M; Walters R S; Smith T L; Keating M J; Barlogie B; McCredie K B; Freireich E J
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia.
Blood 1988;72(5):1784-9.
1988: Epstein J; Barlogie B; Katzmann J; Alexanian R
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.
Blood 1988;71(4):861-5.
1988: Selvanayagam P; Blick M; Narni F; van Tuinen P; Ledbetter D H; Alexanian R; Saunders G F; Barlogie B
Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.
Blood 1988;71(1):30-5.
1987: Narni F; Selvanayagam P; Barlogie B; Saunders G F
HLA-associated invariant chain gene expression in human B cell neoplasia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1987;1(6):504-7.
1985: Barlogie B; Alexanian R; Dixon D; Smith L; Smallwood L; Delasalle K
Prognostic implications of tumor cell DNA and RNA content in multiple myeloma.
Blood 1985;66(2):338-41.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Bart Barlogie

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Bart Barlogie (preview)

All Publications